See more : Hazama Ando Corporation (HAZAF) Income Statement Analysis – Financial Results
Complete financial analysis of ACADIA Pharmaceuticals Inc. (ACAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ACADIA Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nissin Shoji Co.,Ltd. (7490.T) Income Statement Analysis – Financial Results
- Synchrony Financial (SYF-PA) Income Statement Analysis – Financial Results
- Wi-Fi TV, Inc. (WIFT) Income Statement Analysis – Financial Results
- Unicharm Corporation (UNICY) Income Statement Analysis – Financial Results
- Standard Chartered PLC (SCBFY) Income Statement Analysis – Financial Results
ACADIA Pharmaceuticals Inc. (ACAD)
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 726.44M | 517.24M | 484.15M | 441.76M | 339.08M | 223.81M | 124.90M | 17.33M | 61.00K | 120.00K | 1.15M | 4.91M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
Cost of Revenue | 45.73M | 10.17M | 19.14M | 20.55M | 19.60M | 18.33M | 13.06M | 4.41M | 76.37M | 60.60M | 26.72M | 18.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 680.71M | 507.07M | 465.00M | 421.21M | 319.48M | 205.48M | 111.84M | 12.93M | -76.31M | -60.48M | -25.58M | -13.89M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
Gross Profit Ratio | 93.70% | 98.03% | 96.05% | 95.35% | 94.22% | 91.81% | 89.54% | 74.58% | -125,095.08% | -50,401.67% | -2,233.80% | -283.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 351.62M | 361.58M | 239.42M | 319.13M | 240.39M | 187.16M | 149.19M | 99.28M | 73.87M | 60.60M | 26.72M | 18.79M | 17.31M | 20.58M | 41.59M | 56.75M | 57.94M | 49.40M | 30.85M | 23.45M | 16.94M | 14.92M | 13.09M | 9.73M |
General & Administrative | 393.07M | 363.59M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
Selling & Marketing | 9.40M | 5.50M | 41.80M | 51.10M | 38.30M | 39.80M | 15.60M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 402.47M | 369.09M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
Other Expenses | 0.00 | 3.54M | 2.33M | -997.00K | 997.00K | -1.84M | 3.98M | 1.33M | 2.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.56M | 7.53M | 2.36M | 0.00 | 0.00 | 2.15M | 2.85M |
Operating Expenses | 754.09M | 730.67M | 635.44M | 707.79M | 566.02M | 452.92M | 404.25M | 285.74M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
Cost & Expenses | 799.82M | 740.83M | 654.58M | 728.34M | 585.62M | 471.25M | 417.31M | 290.15M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
Interest Income | 17.23M | 6.61M | 591.00K | 6.61M | 11.17M | 5.35M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 82.00K | 409.00K | 2.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 6.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 86.00K | 181.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 5.55M | 2.03M | 3.34M | 2.93M | 2.77M | 3.01M | 2.71M | 1.83M | 647.00K | 206.00K | 79.00K | 109.00K | 285.00K | 607.00K | 1.11M | 1.04M | 768.00K | -146.00K | 1.03M | 1.31M | 1.34M | 1.40M | 0.00 | 0.00 |
EBITDA | -67.83M | -221.57M | -167.10M | -286.59M | -243.78M | -244.44M | -289.70M | -270.99M | -163.47M | -93.02M | -38.22M | -20.78M | -22.48M | 15.70M | -44.36M | -66.98M | -62.65M | -49.05M | -32.93M | -24.18M | -12.40M | -11.22M | -15.28M | -11.27M |
EBITDA Ratio | -9.34% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,337.82% | -425.64% | -1,091.78% | 37.26% | -693.19% | -4,212.45% | -819.14% | -646.92% | -317.45% | -538.40% | -168.01% | -178.84% | -411.39% | -261.34% |
Operating Income | -73.38M | -223.60M | -170.44M | -286.59M | -246.55M | -247.44M | -292.41M | -272.82M | -164.61M | -93.23M | -38.30M | -20.89M | -22.85M | 15.09M | -45.47M | -66.98M | -62.65M | -49.05M | -35.81M | -26.10M | -13.74M | -12.63M | -15.28M | -11.27M |
Operating Income Ratio | -10.10% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,344.72% | -425.64% | -1,105.56% | 35.82% | -710.55% | -4,212.45% | -829.31% | -603.15% | -326.81% | -566.76% | -186.22% | -201.19% | -411.39% | -261.34% |
Total Other Income/Expenses | 22.34M | 10.15M | 2.92M | 5.61M | 12.16M | 3.51M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 45.00K | 323.00K | 2.73M | 6.26M | 3.96M | -4.55M | 178.20K | 0.00 | 0.00 | 15.28M | 11.27M |
Income Before Tax | -51.04M | -213.44M | -167.52M | -280.97M | -234.38M | -243.94M | -288.28M | -270.05M | -164.11M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | 0.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax Ratio | -7.03% | -41.27% | -34.60% | -63.60% | -69.12% | -108.99% | -230.81% | -1,558.20% | -269,037.70% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 10.25M | 2.53M | 351.00K | 611.00K | 876.00K | 1.26M | 1.12M | 1.34M | 330.00K | -206.00K | 0.00 | -109.00K | 0.00 | 0.00 | 0.00 | -1.04M | 0.00 | -3.86M | -200.00 | -200.00 | 352.60K | 242.30K | 14.41M | 10.19M |
Net Income | -61.29M | -215.98M | -167.87M | -281.58M | -235.26M | -245.19M | -289.40M | -271.39M | -164.44M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | -14.09M | -12.87M | -14.41M | -10.19M |
Net Income Ratio | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% | -1,565.94% | -269,578.69% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | -191.00% | -205.05% | -387.88% | -236.41% |
EPS | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -9.66 | -8.86 | -11.93 | -9.53 |
EPS Diluted | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -1.24 | -8.86 | -11.93 | -9.53 |
Weighted Avg Shares Out | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 54.87M | 52.18M | 38.59M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 1.46M | 1.45M | 1.21M | 1.07M |
Weighted Avg Shares Out (Dil) | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.72M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 11.37M | 1.45M | 1.21M | 1.07M |
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug
Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed
Source: https://incomestatements.info
Category: Stock Reports